| Authors |
Gyberg, Viveca ; De Bacquer, Dirk ; De Backer, Guy ; Jennings, Catriona ; Kotseva, Kornelia ; Mellbin, Linda ; Schnell, Oliver ; Tuomilehto, Jaakko ; Wood, David ; Rydén, Lars ; Amouyel, Philippe ; Bruthans, Jan ; Conde, Almudena Castro ; Cifkova, Renata ; Deckers, Jaap W ; De Sutter, Johan ; Dilic, Mirza ; Dolzhenko, Maryna ; Erglis, Andrejs ; Fras, Zlatko ; Gaita, Dan ; Gotcheva, Nina ; Goudevenos, John ; Heuschmann, Peter ; Laucevičius, Aleksandras ; Lehto, Seppo ; Lovic, Dragan ; Miličić, Davor ; Moore, David ; Nicolaides, Evagoras ; Oganov, Raphael ; Pająk, Andrzej ; Pogosova, Nana ; Reiner, Zeljko ; Stagmo, Martin ; Störk, Stefan ; Tokgözoğlu, Lale ; Vulic, Dusko |
| Abstract [eng] |
Background: In order to influence every day clinical practice professional organisations issue management guidelines. Cross-sectional surveys are used to evaluate the implementation of such guidelines. The present survey investigated screening for glucose perturbations in people with coronary artery disease and compared patients with known and newly detected type 2 diabetes with those without diabetes in terms of their life-style and pharmacological risk factor management in relation to contemporary European guidelines. Methods: A total of 6187 patients (18–80 years) with coronary artery disease and known glycaemic status based on a self reported history of diabetes (previously known diabetes) or the results of an oral glucose tolerance test and HbA1c (no diabetes or newly diagnosed diabetes) were investigated in EUROASPIRE IV including patients in 24 European countries 2012–2013. The patients were interviewed and investigated in order to enable a comparison between their actual risk factor control with that recommended in current European management guidelines and the outcome in previously conducted surveys. Results: A total of 2846 (46 %) patients had no diabetes, 1158 (19 %) newly diagnosed diabetes and 2183 (35 %) previously known diabetes. The combined use of all four cardioprotective drugs in these groups was 53, 55 and 60 %, respectively. A blood pressure target of <140/90 mmHg was achieved in 68, 61, 54 % and a LDL-cholesterol target of <1.8 mmol/L in 16, 18 and 28 %. Patients with newly diagnosed and previously known diabetes reached an HbA1c <7.0 % (53 mmol/mol) in 95 and 53 % and 11 % of those with previously known diabetes had an HbA1c >9.0 %. |
